#$%^&*AU2017251792A120171130.pdf#####Abstract Invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy have an anti-HER2 Type 1 T helper (ThI) cell immune deficit and a significant risk of recurrent disease. It has been shown that anti-HER2 CD4* T-cell responses incrementally decrease along the breast cancer continuum - a robust response in healthy donors and patients with benign disease, a depressed response in patients with HER2' ductal carcinoma in situ, and a nearly absent response in patients with HER2* IBC. This invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.1/15 C 9999 o E (D M N 0 NN LL C c m o cn: (silo en s jS) esuodseH O^!lelnmno 999 0 E N N Nm 4 c t-o o 0 0 0 sep e e 0o Jm (D N N (sio sOII)ososuGAEfLl Cd)L 0 3 cn. CSOpild~d GA! PB9H 10 ieq wn N
